Technical Analysis for JAGX - Jaguar Animal Health, Inc.

Grade Last Price % Change Price Change
F 0.09 23.32% 0.02
JAGX closed up 23.32 percent on Thursday, March 28, 2024, on 1.37 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Wide Bands Range Expansion 0.00%
Stochastic Buy Signal Bullish 23.32%
NR7 Range Contraction 23.32%
Narrow Range Bar Range Contraction 23.32%
Wide Bands Range Expansion 23.32%
Oversold Stochastic Weakness 23.32%
Narrow Range Bar Range Contraction 30.29%
Wide Bands Range Expansion 30.29%

   Recent Intraday Alerts

Alert Time
50 DMA Resistance about 16 hours ago
Rose Above 50 DMA about 16 hours ago
Rose Above 20 DMA about 16 hours ago
20 DMA Resistance about 17 hours ago
Up 10% about 17 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Jaguar Animal Health, Inc. Description

Jaguar Animal Health, Inc., a development-stage animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of CID and general acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and general acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend and NP-500. The company was founded in 2013 and is headquartered in San Francisco, California. Jaguar Animal Health, Inc. is a subsidiary of Napo Pharmaceuticals, Inc.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Gastrointestinal Animal Health Dog Gastroenterology Prescription Drugs Colitis Drug Products Diarrhea Gastrointestinal Tract Gastrointestinal Products

Is JAGX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 1.22
52 Week Low 0.0512
Average Volume 44,278,574
200-Day Moving Average 0.30
50-Day Moving Average 0.08
20-Day Moving Average 0.08
10-Day Moving Average 0.07
Average True Range 0.02
RSI (14) 54.55
ADX 20.05
+DI 35.87
-DI 20.43
Chandelier Exit (Long, 3 ATRs) 0.12
Chandelier Exit (Short, 3 ATRs) 0.10
Upper Bollinger Bands 0.12
Lower Bollinger Band 0.04
Percent B (%b) 0.6
BandWidth 92.68
MACD Line 0.00
MACD Signal Line -0.01
MACD Histogram 0.0017
Fundamentals Value
Market Cap 4.56 Million
Num Shares 50.8 Million
EPS -0.87
Price-to-Earnings (P/E) Ratio -0.10
Price-to-Sales 0.46
Price-to-Book 3.12
PEG Ratio -0.02
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.12
Resistance 3 (R3) 0.11 0.10 0.11
Resistance 2 (R2) 0.10 0.10 0.10 0.11
Resistance 1 (R1) 0.10 0.09 0.10 0.10 0.11
Pivot Point 0.08 0.08 0.09 0.09 0.08
Support 1 (S1) 0.08 0.08 0.08 0.08 0.07
Support 2 (S2) 0.07 0.07 0.07 0.07
Support 3 (S3) 0.06 0.07 0.07
Support 4 (S4) 0.06